Targeting both IL-10 and PD-1 by neutralizing antibodies, but not PD-1 alone, resulted in reduced tumour burden, augmented adaptive anti-tumour immunity and thus enhancement in survival of tumour-bearing mice. The gene discussed is PDCD1; the disease is neoplasm.